TOBI

DRUG3 trials

Sponsors

Novartis Pharmaceuticals, Universitaire Ziekenhuizen KU Leuven, Unity Health Toronto

Conditions

Burkholderia Cepacia InfectionCystic FibrosisTreatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients

Phase 1

Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex

CompletedNCT02212587

Unity Health TorontoBurkholderia Cepacia Infection, Cystic Fibrosis

Start: 2014-09-30End: 2016-05-31Updated: 2020-11-04

Phase 3

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

CompletedNCT01082367

Novartis PharmaceuticalsTreatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients

Start: 2010-04-30End: 2015-06-30Updated: 2016-07-15

Phase 4

Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis

CompletedNCT01400750

Universitaire Ziekenhuizen KU LeuvenCystic Fibrosis

Start: 2001-08-31End: 2011-05-31Updated: 2011-08-04

Related Papers

Eradication of early P. aeruginosa infection in children <7 years of age with cystic fibrosis: The early study.

2018-04-2127 citations